Department of Neonatology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Trials. 2024 Oct 23;25(1):711. doi: 10.1186/s13063-024-08530-x.
SafeBoosC-III is a pragmatic, multinational clinical trial evaluating cerebral oximetry-guided treatment for extremely preterm infants. In total, 1601 infants were randomised across 70 sites in Asia, Europe, and USA. To enhance data quality and patient care, a web-based training program was implemented for staff. We now report on the processes.
All training modules consisted of initial learning material followed by a case-based quiz, with elaborate responses to correct as well as to wrong answers. Modules covered trial introduction, cerebral oximetry monitoring, treatment guidelines, cerebral ultrasound, and Good Clinical Practice. The introduction module was accessible in eight languages on an online platform, while language versions varied for other modules, due to different needs. Certification was earned upon module completion, relevant to the staff category. The training was not mandatory, but for motivational purposes, principal investigators continuously received local certification rate reports.
A total of 926 out of 2347 staff (39%) obtained certification. Amongst 295 staff who completed the evaluation, 83% rated the program as overall good and 94% found it relevant to clinical practice. Sites exhibited varying certification rates, with 10 at 0%, 43 between 0.1 and 79.9%, and 17 exceeding 80%. There was no correlation between the rate of certification in individual sites and how often the clinical management was changed due to cerebral hypoxia nor a correlation to site-specific estimates of the intervention effect.
Despite language barriers and a low budget, our web-based training and certification program proved feasible. Only a minority of sites reached 80% certification of staff and an impact on the trial could not be detected.
The SafeBoosC-III trial is registered at ClinicalTrials.gov NCT03770741. The first participant was randomised in June 2019 and recruitment was completed in December 2021.
SafeBoosC-III 是一项实用的、多国家的临床试验,旨在评估脑氧饱和度指导治疗极早产儿。总共有 1601 名婴儿在亚洲、欧洲和美国的 70 个地点被随机分组。为了提高数据质量和患者护理,为工作人员实施了一个基于网络的培训计划。我们现在报告相关流程。
所有培训模块都包含初始学习材料,然后是基于案例的测验,对正确和错误答案都有详细的解释。模块涵盖了试验介绍、脑氧饱和度监测、治疗指南、脑超声和良好临床实践。介绍模块可在一个在线平台上以八种语言访问,而其他模块的语言版本则因需求不同而有所不同。完成特定模块后即可获得相关工作人员类别的认证。培训并非强制性的,但为了激励目的,主要研究者会持续收到当地认证率报告。
在 2347 名工作人员中,共有 926 名(39%)获得了认证。在完成评估的 295 名工作人员中,83%认为该计划整体良好,94%认为它与临床实践相关。各站点的认证率存在差异,有 10 个站点为 0%,43 个站点为 0.1%至 79.9%,17 个站点超过 80%。个别站点的认证率与因脑缺氧而改变临床管理的频率之间没有相关性,也与特定站点的干预效果估计值之间没有相关性。
尽管存在语言障碍和低预算,我们的基于网络的培训和认证计划仍被证明是可行的。只有少数站点达到了 80%的工作人员认证率,并且没有发现对试验的影响。
SafeBoosC-III 试验在 ClinicalTrials.gov 注册,编号为 NCT03770741。第一个参与者于 2019 年 6 月随机分组,招募工作于 2021 年 12 月完成。